• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Defining resectability: When do you try to take it out?

作者信息

Etienne Harry, Battilana Bianca, Spicer Jonathan, Werner Raphael S, Opitz Isabelle

机构信息

Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

Department of Surgery, McGill University Health Center, Montreal, Québec, Canada.

出版信息

JTCVS Open. 2024 Mar 29;19:338-346. doi: 10.1016/j.xjon.2024.03.012. eCollection 2024 Jun.

DOI:10.1016/j.xjon.2024.03.012
PMID:39015436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11247203/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e809/11247203/a3b83e63743f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e809/11247203/bd5d51b2df7e/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e809/11247203/a3b83e63743f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e809/11247203/bd5d51b2df7e/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e809/11247203/a3b83e63743f/gr1.jpg

相似文献

1
Defining resectability: When do you try to take it out?定义可切除性：何时尝试切除？
JTCVS Open. 2024 Mar 29;19:338-346. doi: 10.1016/j.xjon.2024.03.012. eCollection 2024 Jun.
2
The oncologic efficacy of extended resections for lung cancer.肺癌扩大切除术的肿瘤学疗效。
J Surg Oncol. 2023 Feb;127(2):296-307. doi: 10.1002/jso.27183.
3
Resectability versus Operability in Early-Stage Non-Small Cell Lung Cancer.早期非小细胞肺癌的可切除性与可手术性
Curr Oncol Rep. 2024 Jan;26(1):55-64. doi: 10.1007/s11912-023-01477-3. Epub 2023 Dec 22.
4
Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.局部进展期胰腺导管腺癌可切除性判断的共识——Conko-007 多中心试验结果。
BMC Cancer. 2019 Oct 22;19(1):979. doi: 10.1186/s12885-019-6148-5.
5
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.既往胸部放疗对晚期非小细胞肺癌免疫检查点抑制剂疗效的影响。
Jpn J Clin Oncol. 2021 Feb 8;51(2):279-286. doi: 10.1093/jjco/hyaa180.
6
Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report.局部晚期非小细胞肺癌患者在接受PD-1抑制剂诱导治疗及手术后发生连续性严重免疫相关不良事件：一例报告
Transl Lung Cancer Res. 2021 Aug;10(8):3682-3688. doi: 10.21037/tlcr-21-603.
7
The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.局部晚期非小细胞肺癌诱导放化疗后手术的长期疗效。
Case Rep Oncol. 2014 Oct 23;7(3):700-10. doi: 10.1159/000368598. eCollection 2014 Sep.
8
Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors.目前 IIIA（N2）期非小细胞肺癌的治疗管理：围手术期免疫治疗和酪氨酸激酶抑制剂的作用。
Thorac Surg Clin. 2023 May;33(2):189-196. doi: 10.1016/j.thorsurg.2023.01.006. Epub 2023 Feb 26.
9
Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection.PD-1 免疫检查点抑制剂在合并慢性感染的局部晚期和晚期非小细胞肺癌患者中的疗效和安全性。
Oncol Res Treat. 2022;45(6):366-374. doi: 10.1159/000523854. Epub 2022 Mar 1.
10
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.诱导治疗后潜在可切除的 III 期非小细胞肺癌患者的扩大切除术。
J Thorac Cardiovasc Surg. 2022 Dec;164(6):1587-1602.e5. doi: 10.1016/j.jtcvs.2022.03.034. Epub 2022 Apr 18.

引用本文的文献

1
Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy: A Single Institution Experience.新辅助化疗免疫治疗后可切除的局部晚期非小细胞肺癌的疗效：单机构经验
J Clin Med. 2025 Feb 4;14(3):988. doi: 10.3390/jcm14030988.
2
Updates in Management of Unresectable Stage III Non Small Cell Lung Cancer: A Radiation Oncology Perspective.不可切除的 III 期非小细胞肺癌的管理进展：放射肿瘤学视角
Cancers (Basel). 2024 Dec 19;16(24):4233. doi: 10.3390/cancers16244233.

本文引用的文献

1
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.可切除非小细胞肺癌患者围手术期替雷利珠单抗联合化疗：Neotorch 随机临床试验。
JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735.
2
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.可切除非小细胞肺癌的围手术期度伐利尤单抗治疗。
N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23.
3
Prognostic significance of uncertain resection for metastasis in the highest mediastinal lymph node after surgery for clinical N0 non-small cell lung cancer.
临床N0期非小细胞肺癌手术后上纵隔淋巴结转移不确定切除的预后意义。
Front Surg. 2023 Jun 15;10:1115696. doi: 10.3389/fsurg.2023.1115696. eCollection 2023.
4
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.III 期非小细胞肺癌的围手术期纳武利尤单抗和化疗。
N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28.
5
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
6
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.美国国立综合癌症网络（NCCN）指南见解：非小细胞肺癌，2023年第2版
J Natl Compr Canc Netw. 2023 Apr;21(4):340-350. doi: 10.6004/jnccn.2023.0020.
7
IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer.IASLC 肺癌分期项目：为第九版肺癌 TNM 分期分类修订提供新数据库。
J Thorac Oncol. 2023 May;18(5):564-575. doi: 10.1016/j.jtho.2023.01.088. Epub 2023 Feb 10.
8
Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review.不可切除的IIIC期非小细胞肺癌转化为根治性手术：抗PD-1免疫疗法联合化疗及抗血管生成治疗 1例报告及文献复习
Front Oncol. 2022 Sep 14;12:954685. doi: 10.3389/fonc.2022.954685. eCollection 2022.
9
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.诱导治疗后潜在可切除的 III 期非小细胞肺癌患者的扩大切除术。
J Thorac Cardiovasc Surg. 2022 Dec;164(6):1587-1602.e5. doi: 10.1016/j.jtcvs.2022.03.034. Epub 2022 Apr 18.
10
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.